Pantethine-15N2

Pantethine-15N2 is the 15N2 labeled Pantethine. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration[1][2][3][4][5][6].

Product Specifications

Product Name Alternative

D-Pantethine-15N2; LBF disulfide-15N2

UNSPSC

12352211

Target

Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Others

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Endocrinology; Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pantethine-15n2.html

Solubility

10 mM in DMSO

Smiles

O=C([15NH]CCSSCC[15NH]C(CCNC([C@H](O)C(C)(C)CO)=O)=O)CCNC([C@H](O)C(C)(C)CO)=O

Molecular Formula

C22H42N2 15N2O8S2

Molecular Weight

556.71

References & Citations

[1]Bocos C, et al. Pantethine stimulates lipolysis in adipose tissue and inhibits cholesterol and fatty acid synthesis in liver and intestinal mucosa in the normolipidemic rat. Environ Toxicol Pharmacol. 1998 Aug 4;6 (1) :59-66.|[2]Abou-Hamdan M, et al. Potential antiviral effects of pantethine against SARS-CoV-2. Sci Rep. 2023 Feb 8;13 (1) :2237.|[3]Penet MF, et al. Effect of Pantethine on Ovarian Tumor Progression and Choline Metabolism. Front Oncol. 2016 Nov 16;6:244.|[4]Tóth F, et al. Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid. Int J Mol Sci. 2021 Jan 2;22 (1) :403.|[5]Kavian N, et al. Pantethine Prevents Murine Systemic Sclerosis Through the Inhibition of Microparticle Shedding. Arthritis Rheumatol. 2015 Jul;67 (7) :1881-90. |[6]Brunetti D, et al. Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model. Brain. 2014 Jan;137 (Pt 1) :57-68.